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COMBINED RISK-FACTOR ANALYSIS PREDICTS OUTCOME OF AML PA-
TIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOW-
ING REDUCED INTENSITY CONDITIONING
Hemmati, P.G.1, Terwey, T.H.1, Massenkeil, G.2, le Coutre, P.1,
Neuburger, S.1, Dorken, B.1, Arnold, R.1 1Charite University Medicine
Berlin, Berlin, Germany; 2Guetersloh General Hospital, Guetersloh,
Germany
Reduced intensity conditioning (RIC) allowed to offer allogeneic
stem cell transplantation (alloSCT) to patients ineligible to standard
conditioning. In addition to a number of disease-specific variables,
the presence of comorbidities, as assessed by the hematopoietic
cell transplantation-specific comorbidity index (HCT-CI), and
transplantation-associated factors affect the outcome of these
patients following allSCT.We therefore investigatedwhether a com-
bined risk-factor analysis predicts the overall outcome of patients
with AML following RIC-alloSCT. 90 patients with AML who
underwent alloSCT at our institution were analyzed. 50/90 patients
(56%) were in CR1, 12/90 (15%) were in .CR1, and 26/90 (29%)
had active disease. 4/90 patients (4%) had a favorable-risk karyotype,
51/90 patients (57%) or 29/90 patients (32%) had an intermediate-
risk or a poor-risk karyotype. 18/90 (20%) patients had an interme-
diate-risk HCT-CI and 72/90 patients (80%) had an unfavorable
score. 38/90 patients (42%) were transplanted from a matched-
related donor. A matched-unrelated or a mismatched-unrelated
donor was available in 36/90 patients (40%) or in 16/90 patients
(18%). As a preparative regimen all patients received RIC (fludara-
bine 180mg/m21 oral busulfane 8mg/kg1 antithymocyte globulin
40 mg/kg). Overall survival (OS) or disease-free survival (DFS) of all
patients at 1, 3, and 5 years was 60%, 44%, and 44% or 56%, 46%,
and 46%. 49/90 patients (54%) are in CR. Causes of death were
relapse (23/90 patients (26%)) or TRM (18/90 patients (20%)).
Depending on the presence or absence of at least one leukemia-
specific risk-factor (tAML, unfavorable-risk karyotype, .CR1) or
transplantation-related risk-factor (alloSCT from a mismatched or
an unrelated donor), patients were grouped into four subgroups:
group I (HCT-CI # 4, no high-risk), group II (HCT-CI .4, no
high-risk), group III (HCT-CI # 4, high-risk), and group IV
(HCT-CI .4, high-risk). Projected OS in at 1, 2, and 4 years after
alloSCT was 75%, 63%, and 63% (group I), 100%, 67%, and
67% (group II), 58%, 45%, and 36% (group III), or 31%, 15%,
and 15% (group IV), which differed significantly between the sub-
groups (p 5 0.01). There was no statistically significant difference
in TRM between the subgroups (p 5 0.27). This indicates that
a combined risk-factor analysis incorporating disease-specific vari-
ables, transplantation-related factors, and comorbidities may predict
the overall outcome of patients with AML after RIC-alloSCT.154
POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) OUT-
COMES IN PATIENTS WITH AML TRANSPLANTED PRIOR TO ACHIEVING
PLATELET RECOVERY
Alatrash, G.1, Pelosini, M.2, Saliba, R.1, Rondon, G.1, Zhang, W.1,
Giralt, S.1, Kebriaei, P.1, Alousi, A.1, Khouri, I.1, Champlin, R.1, de
Lima, M.1 1UTMDAnderson Cancer Center, Houston, TX; 2University
of Pisa, Pisa, Italy
Complete remission (CR) after chemotherapy for AML is defined
by\5% blasts in bone marrow (BM) and peripheral blood platelet
count .100K/ml. This remains the primary goal following chemo-
therapy; however, many patients proceed to HSCT without ever
achieving the platelet goal (CRp). With new therapies, the
number of patients transplanted in CRp is increasing. We sought
to determine if CRp was a worse prognosticator compared to
classically-defined CR.
Methods: A cohort of 427 patients was used. Disease status at
HSCT included: first CR (CR1); second CR (CR2); first CRp
(CRp1): patients with \5% BM blasts but not platelet recovery
following induction chemotherapy; primary induction failure
(PIF): no CR following induction therapy; CRp2: patients who after
therapy for first relapse achieved\5% BM blasts but not platelet
recovery; refractory (rel): patients in first relapse not responding to
salvage therapy. CRp was assigned only if patients were thrombocy-
topenic $30 days from the last day of chemotherapy to the start ofHSCT conditioning. Diagnoses included AML (n 5 376) or high-
risk MDS (n 5 51). Conditioning regimens used: TBI-based (2%;
n 5 8), oral/IV busulfan based-ablative regimens (61%; n 5 261),
fludarabine/melphalan-based reduced intensity conditioning regi-
mens (RIC) (36%; n5 153), or other (1%; n5 5). Fifty-eight percent
(n5 248) and 42% (n5 179) of patients received matched sibling or
unrelated donor (UD) HSCT, respectively
Results:Median age was 50 years (range 6–74). At time of HSCT,
disease status was CR1 in 38% (n 5 164), CR2 in 24% (n 5 102),
CRp1 in 11% (n 5 48), CRp2 in 7% (n 5 30), PIF 11% (n 5 47),
and rel1 8% (n5 36). Poor-risk cytogenetics were evenly distributed
in patients in CR1 (39%) Vs. CRp1 (44%) and in CR2 (15%) Vs.
CRp2 (24%). Fifty-one percent of patients died (n 5 219); 31%
(n 5 134) progressed. Overall survival (OS) at 36-months was
49%. Among survivors, median follow-up is 42 months (range 3–
131months). Hazard ratios for non-relapse mortality (NRM) and
OS at 1-year (Table) favored patients receiving HSCT in CR1 (vs.
CRp1 or PIF), or in CR2 (vs. CRp2 or rel1).
Conclusion: Significantly better OS and NRM were seen follow-
ing HSCT for patients in CR compared to CRp. CRp conferred an
intermediate prognostic status, better than refractory disease, but
significantly worse than ‘classic’ CR. Achieving a CR prior to
HSCT should remain the gold standard for patients with AML or
MDS receiving allogeneic HSCT.
Table. Hazard Ratios (HR) for non-relapse mortality (NRM)
and overall survival (OS) at 1 year. CR1 is used as the reference
group.
NRM OSCR1 (n5164) Reference Reference
CR2 (n5102) 1.4 (p50.3) 1.3 (p50.3)
CRp1 (n548) 2.4 (p50.01) 2.4 (p50.001)
CRp2 (n530) 1.7 (p50.2) 1.9 (p50.05)
PIF (n547) 3.7 (p50.001) 3.6 (p50.001)
First relapse (n536) 4.6 (p50.001) 6.7 (p50.001)CR5complete remission; CRp5pathologic CR; PIF5primary induction
failure.155
POLYCLONAL PRAME-SPECIFIC CYTOTOXIC T LYMPHOCYTES GENER-
ATED USING PROTEIN-SPANNING POOLS OF OVERLAPPING PENTADE-
CAPEPTIDES TARGET CHRONIC MYELOID LEUKEMIA
Quintarelli, C.1,2, Dotti, G.1, De Angelis, B.1,2, Hoyos, V.1, Pane, F.3,
Mims, M.4, Heslop, H.1, Rooney, C.M.1, Brenner, M.K.1, Savoldo, B.1
1Baylor College of Medicine, Houston, TX; 2FedericoII’’ University,
Naples, Italy; 3FedericoII’’ University, Naples, Italy; 4Baylor College of
Medicine, Houston, TX
Following allogeneic hematopoietic stem cell transplantation,
GVL is likely mediated not only by alloreactive T cells, but also
by donor lymphocytes recognizing tumor associated antigens over-
expressed by leukemic cells. Selective expansion of tumor-specific
CTLs could augment GVL without increasing the risk of
GVHD. The cancer testis antigen PRAME is a potential target
for adoptive immunotherapy of hematologic and solid tumors.
We have shown that PRAME-CTL can be expanded ex vivo, using
a combination of artificial antigen presenting cells (aAPC) (K562
cell line genetically modified to express the HLA-A*02 and costi-
mulatory molecules) and cytokines. Four HLA-A*02 PRAME-de-
rived epitopes have previously been identified using a proteosome
mediated digestion analysis, that relying only on the major cleavage
site of the immune proteosome, may limit their relevance. We have
now adopted a method that uses a 125 overlapping pentadecapep-
tides library spanning whole PRAME protein. We evaluated
whether novel immunogenic HLA-A*02-restricted epitopes can
be identified and used to consistently generate polyclonal
PRAME-CTL lines from healthy donors and patients with hema-
tologic malignancies. CD81 T cells from 14 healthy donors and
5 patients with chronic myelogenenous leukemia (CML) were
primed with autologous CD40L-activated B blasts loaded with
the PRAME library in the presence of IL12, IL7 and IL15, and
then expanded by weekly stimulation with peptide loaded aAPC
Poster Session-I 59and IL2. Using this approach we consistently generated PRAME-
CTLs in 12/14 HLA-A*02 healthy donors (526 6 101 SFC/105
cells as assessed by IFNg Elispot assay). Similarly, PRAME-
CTLs were generated from all 5 CML patients (630 6 120 SFC/
105 cells). These PRAME-CTLs were also able to target autolo-
gous tumor blasts (57 6 6 IFNg SFC/105), demonstrating that
the same peptides were presented physiologically. A Cr51 release
assay confirmed that the PRAME-reactive T cells were cytotoxic,
lysing autologous-PHA blasts loaded with PRAME-library (63 6
14% at a 20:1 E:T ratio), but not with irrelevant library. Using sub-
pools, we found that the responses of our expanded PRAME-CTLs
were polyclonal, since they consistently released IFNg in response
to 1 to 6 pentadecapeptides pools. Moreover, this approach has al-
lowed to identify 6 potential new immunogenic 15mer peptides
that are processed and presented by tumor cells, and should facili-
tate expansion of polyclonal PRAME-CTLs for adoptive transfer
in patients with PRAME1 malignancy.156
GVHD PROPHYLAXIS USING LOW-DOSE CYCLOSPORINE IS SAFE AND
REDUCES THE RISK OF RELAPSE AND DEATH IN LEUKEMIC RECIPIENTS
OF HLA-IDENTICAL SIBLING TRANSPLANTS
Olsson, R., Remberger, M., Mattsson, J., Hassan, Z., Ringden, O.
Karolinska University Hospital, Stockholm, Sweden
Four doses of methotrexate (MTX) and low-dose cyclosporine
(CsA), starting at 1 mg/kg/day i.v. with early discontinuation, were
given to 171 consecutive HLA-identical sibling recipients with leu-
kaemia. Apart from MTX, retrospective controls (n 5 40) received
CsA starting at 5–7.5 mg/kg/day i.v., and discontinued 1 year post-
transplant. The target CsA trough levels were 100 ng/ml and 200–
300 ng/ml in the low-dose and the control group, respectively. In
the low-dose group, the risk of acute GVHD grades I-II was aug-
mented (66% vs. 49%, p\0.01), whereas grades III-IV did not differ
between the groups (9% vs. 8%). The risk of chronic GVHD was
markedly increased in those receiving low-dose CsA (50% vs.
29%, p\ 0.01), and the cumulative proportion of relapse at 5 years
post-transplant was increased in the control group (51% vs. 26%,
p\ 0.01). Moreover, the 5-year survival rate was 63% in the low-
dose group compared to 40% in the controls (P5 0.04). In a multi-
variate analysis, low-dose CsA was the only factor associated with
acute GVHD grades I-IV (RH 2.40, P 5 0.02). Significant predic-
tors of chronic GVHD were low-dose CsA (RH 2.56, p\ 0.01),
chronic myeloid leukaemia (RH 1.92, p\0.01), and administration
of donator lymphocyte infusions (RH 1.66, P5 0.03). The risk of re-
lapse was counteracted by chronic GVHD (RH 0.46, p \ 0.01),
whereas chronic GVHD (RH 0.53, p \ 0.01) and acute GVHD
grades III-IV (RH 4.35, p\0.01) were the strongest factors associ-
ated with patient death. Importantly, the transplant-related mortal-
ity at 5 years post-transplant was similar in the low-dose CsA and
control groups (18% and 20%, respectively, P 5 0.58). In conclu-
sion, a low-dose CsA regimen in leukemic recipients of HLA-iden-
tical sibling transplants increases the rate of chronic GVHD,
which seems to attenuate the risk of relapse, thereby improving pa-
tient survival.157
ISOLATED EXTRA-MEDULLARY RELAPSE OF ACUTE LEUKEMIA AFTER
ALLOGENEIC STEM-CELL TRANSPLANTATION (SCT); DIFFERENT KINET-
ICS AND BETTER PROGNOSIS THAN SYSTEMIC RELAPSE
Shimoni, A., Rand, A., Shem-Tov, N., Yerushalmi, R., Hardan, I.,
Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer, Israel
Allogeneic SCT is a potentially curative treatment for acute leu-
kemia, however relapsing disease is the major cause of treatment
failure. Isolated extramedullary (IEM) relapse is considered a rare
event and its characteristics and prognosis are less defined than sys-
temic relapse. We analyzed outcomes of 356 consecutive pts with
AML/MDS (n 5 277) and ALL (n 5 79) given SCT in a single in-
stitution. With a median follow-up of 30 months (range, 1–103),
149 pts relapsed (122 died). The overall survival rate was 34%
(95CI, 27–41) and the cumulative incidence of relapse 47%(95CI, 42–54). 17 pts had IEM relapse (11.4% of all first relapses);
CNS (n 5 6), mediastinum (n 5 2), pleura (n 5 2), skin (n 5 2),
breast (n 5 2), bone (n 5 1), other soft tissue masses (n 5 2).
IEM relapse occurred later after SCT than systemic relapse; me-
dian 14 (1–38) and 3 (1–59) months, respectively (p 5 0.002). Pts
with an IEM relapse were younger, median age 38 and 46 years, re-
spectively (p 5 0.02). IEM relapse occurred more commonly in
ALL (23% of relapses) than MDS/AML (8%, P 5 0.02). There
was a trend for higher incidence in pts transplanted in remission
(16% of relapses) than in pts transplanted in active disease (8%,
p 5 0.09). There was no relation to donor or conditioning type. In-
terestingly, among 14 pts having IEM relapse more than 3 months
after SCT, 11 had a history of chronic GVHD (79%), compared
with 29 of 70 pts with systemic relapse (41%, p 5 0.01). Pts with
IEM relapse were most often treated with systemic chemotherapy,
followed by radiation therapy and DLI when feasible. Pts with sys-
temic relapse were treated with chemotherapy and DLI or a second
SCT. Among the 17 pts with IEM relapse, 12 achieved CR (71%),
5 remained in continuous CR, 7 relapsed again, 2 systemic (both
died), 5 EM (2 are in long-term remission). Among the 132 pts
with systemic relapse, 35 achieved CR (27%), 14 died in remission,
7 remained in continuous CR, 14 relapsed again, 9 systemic (all
died), 5 EM (1 is in long-term remission). The median survival af-
ter relapse was 2.5 and 20 months, and the 2-year OS rates 7% and
38% after systemic and IEM relapse, respectively (p 5 0.0002). In
conclusion, IEM relapse of acute leukemia after SCT is relatively
common. It occurs later than systemic relapse and more commonly
in pts with chronic GVHD, suggestive that GVL is able to prevent
systemic recurrence but is less successful in EM sites. When treated
aggressively prognosis is better with IEM relapse and long-term
survival is feasible.158
CONDITIONING REGIMENS PRIOR TO ALLOGENEIC STEM-CELL TRANS-
PLANTATION (SCT) IN ACUTE LEUKEMIA: THE ROLE OF DOSE INTENSITY
Shimoni, A., Rand, A., Hardan, I., Shem-Tov, N., Yerushalmi, R.,
Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer, Israel
Allogeneic SCT with both myeloablative and reduced-intensity
conditioning (RIC) is effective therapy in acute leukemia. To better
define the role of dose intensity in SCT, we retrospectively ana-
lyzed SCT outcomes in 356 consecutive adult patients (pts) with
MDS/AML (n 5 277) and ALL (n 5 79) given SCT over an 8-
year period in a single institution. The median age was 51 (range,
17–75). The donors were HLA-matched siblings (n 5 191),
matched unrelated (n 5 139) and alternative (n 5 26). Pts meeting
standard eligibility criteria were routinely given myeloablative con-
ditioning (MAC, Cy/TBI or BuCy, n 5 141). Pts non-eligible for
MAC were given either RIC (fludarabine and reduced doses of bu-
sulfan or melphalan, n 5 116) or modified myeloablative condi-
tioning (modMAC, fludarabine with myeloablative doses of
busulfan or treosulfan, n 5 99). Disease status at SCT was CR1/
CR2 (n 5 176), previously untreated or untreated relapse (n 5
63) and chemo-refractory (n 5 117). With a median follow-up of
30 months (range 1–103), 159 pts are alive and 197 died; 75 of
treatment-related causes and 122 of relapse. The estimated 5-yr
overall survival (OS) in this relatively high-risk pt group was
34% (95%CI, 27–41). The status of disease at SCT was the most
important factor predicting OS; 48, 31 and 16% for pts in CR, un-
treated or chemo-refractory leukemia, respectively (p\0.001). Mul-
tivariable analysis (MVA) identified SCT not in CR, SCT from
unrelated and alternative donors as adverse prognostic signs with
hazard ratios (HR) of 2.7, 1.5, and 2.2, respectively. The condition-
ing regimen used was not a significant factor in the whole pt group
with 5-yr OS of 38, 35 and 31% after MAC, modMAC and RIC,
respectively (p 5 NS). However, RIC was associated with reduced
OS in 2 subgroups. Among pts with MDS/AML given SCT not in
CR, 5-yr OS was 34, 24 and 13% after MAC, modMAC and RIC,
respectively (p 5 0.03) with HR of 1.6 for RIC in MVA. In the
group of ALL pts, MVA identified RIC and SCT not in CR1 as
adverse prognostic signs with HR of 2.0 (p 5 0.04) and 2.0 (p 5
0.03), respectively. In conclusion, MAC should still be considered
the standard of care for SCT in acute leukemia in eligible pts.
RIC is associated with inferior outcome in pts with ALL and pts
